Pergoveris®

DRUG3 trials

Sponsors

Merck KGaA, Darmstadt, Germany

Conditions

Assisted Reproductive TechniquesInfertilityReproductive Technology, Assisted

Phase 3

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique

CompletedNCT01297465

Merck KGaA, Darmstadt, GermanyAssisted Reproductive Techniques, Reproductive Technology, Assisted

Start: 2011-05-31End: 2012-10-31Updated: 2021-05-28

Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)

CompletedNCT02047227

Merck KGaA, Darmstadt, GermanyInfertility

Start: 2014-01-31End: 2015-08-31Updated: 2017-08-24

Unknown Phase

A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

CompletedNCT01416987

Merck KGaA, Darmstadt, GermanyInfertility

Start: 2011-08-14End: 2018-05-10Updated: 2019-07-19

Related Papers

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.

2017-03-0152 citations

Efficacy and Safety of Pergoveris in Assisted Reproductive Technology—ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment

BMJ Open2015-07-0113 citations